10-Q: Definitive Healthcare Reports Revenue Decline, Goodwill Impairment

Definitive Healthcare Corp. filed its Q2 2026 10-Q, revealing a year-over-year revenue decrease, a substantial goodwill impairment charge, and ongoing challenges with Nasdaq's minimum bid price requirement.

Summary

• Definitive Healthcare Corp. reported a decrease in revenue for both the three-month and six-month periods ended June 30, 2026, compared to the same periods in 2025.
• The company recorded a significant goodwill impairment charge of $197.2 million in the first quarter of 2026, following a $196.1 million charge in fiscal year 2025.
• Definitive Healthcare received a notice from Nasdaq on June 18, 2026, for non-compliance with the minimum bid price requirement, with a deadline of December 15, 2026, to regain compliance.
• Operating expenses decreased year-over-year for the three-month period due to reductions in sales and marketing, product development, and general and administrative expenses, partly offset by an increase in transaction, integration, and restructuring expenses.
• For the six-month period, operating expenses increased due to the goodwill impairment charge, despite decreases in sales and marketing, product development, and general and administrative expenses.
• The company continues to invest in its AI-powered healthcare intelligence platform, Turbo, with an initial pilot planned for the third quarter of 2026.
• Cash and cash equivalents stood at $170.9 million as of June 30, 2026, with $49.7 million available under its revolving credit facility.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue decline, substantial goodwill impairment, and ongoing Nasdaq listing concerns, despite some operational cost controls.

Positives

• The company is investing in its AI-powered healthcare intelligence platform, Turbo, with an initial pilot planned for Q3 2026.
• Operating expenses for the three-month period decreased by 7% due to cost-saving measures.
• Cash and cash equivalents remain substantial at $170.9 million as of June 30, 2026.
• The company has $49.7 million in available borrowing capacity under its revolving credit facility.
• The company expects to make payments for the 2026 Restructuring Plan over the next three months and does not anticipate further material charges.
• The company is seeing modest signs of improvement in the macroeconomic backdrop late in 2025 and through the first half of 2026, including healthier demand trends and improving customer retention.

Negatives

• Revenue decreased by 9% for the three months ended June 30, 2026, and by 7% for the six months ended June 30, 2026, compared to the prior year periods.
• A significant goodwill impairment charge of $197.2 million was recorded in Q1 2026.
• The company received a non-compliance notice from Nasdaq regarding the minimum bid price requirement, with a potential delisting risk.
• Customer churn remains elevated, particularly among smaller customers and in the Life Sciences market, impacting revenue growth.
• Sales execution challenges in 2024 and 2025 continue to impact new customer acquisition and upsell.
• Current remaining performance obligations (cRPO) decreased to $213.4 million from $240.5 million year-over-year.
• Gross profit margin is expected to decrease in 2026 due to revenue declines and a less favorable cost structure compared to the prior year which included one-time credits.

Risks

• Non-compliance with Nasdaq's minimum bid price requirement could lead to delisting, adversely affecting stock price, liquidity, and the ability to raise capital.
• Challenging macroeconomic conditions have contributed to heightened customer churn and are expected to continue impacting revenue growth.
• Sales execution challenges and disruptions from go-to-market team changes in 2024 and 2025 are impacting new customer acquisition and upsell.
• Changes in the healthcare claims data market, including data provider pricing and availability, may negatively impact the cost of acquiring such data.
• The company's substantial indebtedness could adversely affect its business, financial condition, and results of operations.
• The company's dependence on third parties for data and services poses a risk.
• Increased accessibility to free or inexpensive information sources could impact the company's competitive position.
• The company faces risks related to cybersecurity and data breaches.

Future Outlook

The company expects its revenue to decline in 2026 compared to 2025 due to ongoing sales execution challenges and macroeconomic headwinds. Cost of revenue as a percentage of revenue is expected to modestly increase. Gross profit margin is also expected to decrease in 2026. The company anticipates continued investment in its AI-powered platform, Turbo.

Management Comments

• We believe any company selling or competing within the healthcare ecosystem is a potential customer for us and contributes to our estimated current total addressable market of over $11 billion that includes a more focused serviceable addressable market of approximately $7 billion.
• We intend to actively monitor the closing bid price of our common stock and consider available options to regain compliance with the minimum bid price requirement.
• We believe that our cash flow from operations, availability under the 2021 Credit Agreement and available cash and cash equivalents and short-term investments will be sufficient to meet our liquidity needs for at least the next twelve months and in the long term.
• We do not believe inflation has had a material effect on our business, financial condition, or results of operations. However, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset higher costs through price increases and our inability or failure to do so could potentially harm our business, financial condition, and results of operations.

Industry Context

StockSavvy.ai notes that Definitive Healthcare operates in the competitive healthcare data and analytics market. The company's challenges with revenue growth and customer retention, exacerbated by macroeconomic conditions, are not unique to Definitive Healthcare, as many SaaS and data-centric companies are facing similar pressures. The significant goodwill impairment suggests a reassessment of past acquisition valuations in light of current market realities and future growth expectations.

Comparison to Industry Standards

• The company's Net Dollar Retention Rate (NDR) is a key metric for SaaS businesses, but specific industry benchmarks for NDR in the healthcare data analytics sector are not provided in the filing.
• The reported revenue decline and increased customer churn are concerning trends that may be out of step with more resilient segments of the broader technology or healthcare IT industries, though many SaaS companies have experienced similar headwinds.
• The substantial goodwill impairment charge of $197.2 million is a significant event, indicating that the market valuation of the company has fallen considerably below its carrying value, a situation that can occur across various industries during economic downturns or periods of strategic reassessment.

Legal Proceedings

• The company is subject to various legal proceedings, claims, and governmental inspections, audits, or investigations that arise in the ordinary course of business. Management believes the ultimate resolution of these matters will not have a material adverse effect on its financial position, results of operations, or cash flows.

Related Party Transactions

• Recorded revenue from related parties of $0.1 million for Q2 2026 and $0.3 million for the first six months of 2026.
• Paid $1.3 million to related parties in Q2 2026 and $1.9 million in the first six months of 2026 for ordinary course transactions.
• Payables to related parties amounted to $0.6 million as of June 30, 2026.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq could negatively impact share price and liquidity. Revenue decline and goodwill impairment may affect investor confidence.
• Employees: Restructuring plans involving workforce reduction may impact employee morale and job security.
• Customers: Continued investment in AI platform may lead to enhanced services. However, sales execution challenges and potential data market changes could affect service delivery or cost.
• Creditors: The company's debt obligations and compliance with covenants are critical. The company states it is in compliance with its financial covenants.

Next Steps

• Actively monitor the closing bid price of its common stock and consider available options to regain compliance with the Nasdaq minimum bid price requirement.
• Continue investing in the development and pilot program for its AI-powered healthcare intelligence platform, Turbo.
• Manage operating expenses and pursue profitable growth initiatives.
• Evaluate strategic acquisitions and investments that further expand the platform.

Key Dates

Recommendation

The filing indicates significant negative trends including a revenue decline, substantial goodwill impairment, and a critical Nasdaq listing risk. While cost controls are in place and AI investment is ongoing, these positives are overshadowed by the financial deterioration and regulatory concerns, suggesting a sell recommendation for investors prioritizing stability and growth.

Keywords

healthcare data, analytics platform, subscription revenue, goodwill impairment, Nasdaq listing, AI platform, customer churn, revenue decline